Department of Hepatic Oncology, Xiamen Clinical Research Center for Cancer Therapy, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen 361015, China.
Key Laboratory for Carcinogenesis and Cancer Invasion of Chinese Ministry of Education, The Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical School, Fudan University, Shanghai 200032, China.
Medicina (Kaunas). 2022 Sep 24;58(10):1343. doi: 10.3390/medicina58101343.
: To assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed (HAICROX) as an alternative treatment option for advanced hepatocellular carcinoma (HCC) patients who are ineligible for, or failed, the transarterial chemoembolization (TACE) treatment. : From July 2020 to November 2021, a total of 35 HCC patients were enrolled and received HAIC with oxaliplatin plus raltitrexed. The overall survival (OS) and time to progression (TTP) were primary and secondary endpoints, respectively. The tumor response was assessed by the modified response evaluation criteria in solid tumors (mRECIST), and the adverse events were investigated using the common terminology criteria for adverse events version 5.0 (CTCAE 5.0). : The median OS and TTP were 10 months (95% confidence interval (CI): 5.5-14.6) and 3.5 months (95% CI: 2.3-4.7), respectively. By means of multivariate analysis, anti-programmed cell death protein 1 (anti-PD-1) immunotherapy was found to be an independent prognostic factor for better survival. No patients experienced toxicity-related death. Thrombocytopenia, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) elevation were the most common toxicities. No grade 3 or higher adverse events related to HAICROX were observed. : HAICROX showed valuable efficacy and tolerable toxicity in advanced HCC patients who progressed on TACE or were ineligible for TACE. HAICROX is a promising treatment for advanced-stage HCC patients with TACE failure or ineligibility.
评估奥沙利铂联合雷替曲塞肝动脉灌注化疗（HAICROX）作为经动脉化疗栓塞（TACE）治疗失败或不适合 TACE 治疗的晚期肝细胞癌（HCC）患者的替代治疗选择的疗效和安全性。
从 2020 年 7 月至 2021 年 11 月，共纳入 35 例 HCC 患者接受奥沙利铂联合雷替曲塞 HAIC 治疗。总生存期（OS）和无进展生存期（TTP）分别为主要和次要终点。采用实体瘤改良疗效评价标准（mRECIST）评估肿瘤反应，采用不良事件通用术语标准 5.0（CTCAE 5.0）评估不良事件。
中位 OS 和 TTP 分别为 10 个月（95%置信区间 [CI]：5.5-14.6）和 3.5 个月（95%CI：2.3-4.7）。通过多变量分析，抗程序性死亡蛋白 1（抗 PD-1）免疫治疗被发现是生存更好的独立预后因素。无患者因毒性相关死亡。血小板减少、丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）升高是最常见的毒性。未观察到与 HAICROX 相关的 3 级或更高级别的不良事件。
HAICROX 在 TACE 进展或不适合 TACE 的晚期 HCC 患者中显示出有价值的疗效和可耐受的毒性。HAICROX 是 TACE 失败或不适合 TACE 的晚期 HCC 患者的一种有前途的治疗方法。
